Glucose News and Research

RSS

New easy-to-use Bayer blood glucose monitoring system

A new blood glucose monitoring (BGM) system from Bayer, the CONTOUR Next EZ meter and CONTOUR Next test strips, proved easy to use and highly accurate in the hands of intended users -- patients and their healthcare professionals (HCPs) - according to a clinical study presented at the American Diabetes Association 72nd Scientific Sessions in Philadelphia, PA.

11 Jun 2012

Restoration of normal glucose regulation may prevent diabetes

People with pre-diabetes are significantly less likely to develop diabetes if their blood glucose levels are normalized in time, according to new research by the Colorado School of Public Health and the University of Colorado School of Medicine.

11 Jun 2012

Data from first feasibility study of artificial pancreas system

Results from the first feasibility study of an advanced first-generation artificial pancreas system were presented today at the 72nd Annual American Diabetes Association Meeting in Philadelphia. Findings from the study indicated that the Hypoglycemia-Hyperglycemia Minimizer (HHM) System was able to automatically predict a rise and fall in blood glucose and correspondingly increase and/or decrease insulin delivery safely.

11 Jun 2012

Dapagliflozin more effective than sitagliptin for adult patients with type 2 diabetes

Bristol-Myers Squibb Company and AstraZeneca today announced results from a Phase 3 clinical study that showed the investigational compound dapagliflozin 10 mg demonstrated significant reductions in blood sugar levels (glycosylated hemoglobin levels, or HbA1c) compared with placebo at 24 weeks when either agent was added to existing sitagliptin therapy (with or without metformin) in adult patients with type 2 diabetes.

11 Jun 2012

Sanofi’s Lantus more effective than sitagliptin for people with type 2 diabetes

Sanofi announced today that people with early type 2 diabetes uncontrolled on metformin demonstrated superior HbA1c - glycated hemoglobin - reduction with Lantus (insulin glargine [rDNA origin] injection) versus sitagliptin.

11 Jun 2012

Glucose-lowering regulations in people with prediabetes achieves reduction in progression to diabetes in the long term

People with “prediabetes” (a high risk state for overt type 2 diabetes) who experience a period of normal glucose regulation are 56% less likely to develop diabetes 5∙7 years later, according to a new research Article presented at the American Diabetes Association 72nd Scientific Sessions on Saturday 9 June, and published Online First in The Lancet. This is one of four Articles (all presented at the American Diabetes Association 72nd Scientific Sessions) and a Series of three papers that are part of a special Lancet theme issue on diabetes [1].

11 Jun 2012

Amylin announces results from SYMLIN clinical studies on type 2 or 1 diabetes

Amylin Pharmaceuticals, Inc. today announced results from new analyses of previously completed clinical studies demonstrating that patients with type 2 or type 1 diabetes achieved a greater proportion of blood glucose measurements in the normal range when SYMLIN (pramlintide acetate) injection treatment was used along with insulin.

11 Jun 2012

Amylin, Alkermes announce results from BYDUREON clinical study on type 2 diabetes

Amylin Pharmaceuticals, Inc. and Alkermes plc today announced results from the long-term extension of the DURATION-1 study, which showed that BYDUREON (exenatide extended-release for injectable suspension), the first and only once-weekly treatment for type 2 diabetes, was associated with clinically significant and sustained improvements in glycemic control during four years of treatment in adults with type 2 diabetes.

11 Jun 2012

Lilly, Boehringer Ingelheim announce results from linagliptin Phase III trial on T2D

Boehringer Ingelheim and Eli Lilly and Company presented results from a randomised Phase III clinical trial and a post-hoc analysis for linagliptin at ADA.

11 Jun 2012

Lexicon presents six posters on LX4211 at ADA meeting

Lexicon Pharmaceuticals, Inc. will present six posters summarizing the mechanism of action and safety of LX4211, a dual inhibitor of sodium glucose transporters 1 and 2 (SGLT1 and SGLT2) currently in mid-stage development for type 2 diabetes, at the 72nd Scientific Sessions of the American Diabetes Association (ADA) in Philadelphia, Pennsylvania during the Saturday morning poster session on June 9, 2012.

10 Jun 2012

BD, JDRF partner to accelerate development of glucose-sensing technology for T1D

JDRF and BD today announced an extension of their existing collaboration focused on Type 1 diabetes (T1D) to accelerate the development of BD's proprietary glucose-sensing technology which has shown promise in providing very accurate and reliable continuous glucose information.

From BD (Becton, Dickinson and Company) 8 Jun 2012

Researchers identify brain receptor that appears to play a central role in regulating appetite

Researchers at Columbia University Medical Center (CUMC) have identified a brain receptor that appears to play a central role in regulating appetite. The findings, published today in the online edition of Cell, could lead to new drugs for preventing or treating obesity.

8 Jun 2012

Millions of pre-diabetic Americans may be at increased risk of future stroke

Millions of pre-diabetic Americans may be at increased risk of future stroke, say researchers at the University of California, San Diego School of Medicine in a new meta-analysis of epidemiological studies, but the precise degree of that threat is confounded by differing medical definitions and factors that remain unknown or unmeasured.

8 Jun 2012

Studies evaluate transplantation potential and success of islet cells derived from pancreatic tissues

Two studies appearing in the current issue of Cell Transplantation, evaluate the transplantation potential and success of islet cells derived from pancreatic tissues, in addition to a clinical study that reports the occurrence of adverse events.

7 Jun 2012

GLP-1 receptor agonist boosts glycemic control in Asian patients

Adding once-daily lixisenatide to basal insulin treatment is effective at improving glycemic control in Asian patients with Type 2 diabetes, show study findings.

6 Jun 2012

New tool helps researchers to better understand Type 2 human diabetes

With Type 2 human diabetes climbing at alarming rates in the United States, researchers are seeking treatments for the disease, which has been linked to obesity and poor diet. Now biologists at Southern Methodist University, Dallas, report they have developed a new tool that will help researchers better understand this deadly disease.

6 Jun 2012

Investigational diabetes drug appears to improve insulin sensitivity without side effects

Drugs for type 2 diabetes can contribute to weight gain, bone fractures and cardiovascular problems, but in mice, an investigational drug appears to improve insulin sensitivity without those troublesome side effects, researchers at Washington University School of Medicine in St. Louis have shown.

5 Jun 2012

Ancient berry could protect against diabetic retinopathy

The ancient Tibetan goji berry could help fight blindness caused by long-term diabetes according to studies conducted by University of Sydney researchers.

5 Jun 2012

Reumofan Plus may have harmful pharmaceutical ingredients, warns FDA

The U.S. Food and Drug Administration is warning consumers that Reumofan Plus, marketed as a "natural" dietary supplement for pain relief and other serious conditions, contains several active pharmaceutical ingredients not listed on the label that could be harmful.

2 Jun 2012

GPR21 inhibitors may hold promise for diabetes

In recent years, a growing body of evidence has linked inflammation to the development of insulin resistance. In insulin resistance, the hormone insulin is less effective in promoting glucose uptake from the bloodstream into other tissues. Obesity is a major factor that contributes to insulin resistance, which can eventually lead to type 2 diabetes. Previous studies have shown that proinflammatory molecules found in fat tissue decreases sensitivity of tissues to insulin.

2 Jun 2012

Glucose News and Research

New easy-to-use Bayer blood glucose monitoring system

Restoration of normal glucose regulation may prevent diabetes

Data from first feasibility study of artificial pancreas system

Dapagliflozin more effective than sitagliptin for adult patients with type 2 diabetes

Sanofi’s Lantus more effective than sitagliptin for people with type 2 diabetes

Glucose-lowering regulations in people with prediabetes achieves reduction in progression to diabetes in the long term

Amylin announces results from SYMLIN clinical studies on type 2 or 1 diabetes

Amylin, Alkermes announce results from BYDUREON clinical study on type 2 diabetes

Lilly, Boehringer Ingelheim announce results from linagliptin Phase III trial on T2D

Lexicon presents six posters on LX4211 at ADA meeting

BD, JDRF partner to accelerate development of glucose-sensing technology for T1D

Researchers identify brain receptor that appears to play a central role in regulating appetite

Millions of pre-diabetic Americans may be at increased risk of future stroke

Studies evaluate transplantation potential and success of islet cells derived from pancreatic tissues

GLP-1 receptor agonist boosts glycemic control in Asian patients

New tool helps researchers to better understand Type 2 human diabetes

Investigational diabetes drug appears to improve insulin sensitivity without side effects

Ancient berry could protect against diabetic retinopathy

Reumofan Plus may have harmful pharmaceutical ingredients, warns FDA

GPR21 inhibitors may hold promise for diabetes

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News